Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19667626 | 0.86 | BRD4 (0.41) | KLK7NAAAKLK5PRSS1PRSS2 | |
| SCHEMBL19684909 | 0.83 | KLK7 (0.41) | KLK7PTPN1FFAR1PTGER4PTGER3 | |
| SCHEMBL19684899 | 0.73 | PRKCA (0.38) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL20873490 | 0.73 | BRD4 (0.43) | NAAAFFAR1 | |
| SCHEMBL20873489 | 0.73 | BRD4 (0.43) | NAAAFFAR1 | |
| SCHEMBL19684906 | 0.72 | PTPN1 (0.41) | PTPN1FFAR1PTGER4PTGER3PTGER2 | |
| SCHEMBL19667670 | 0.71 | KLK7 (0.42) | KLK7FFAR1GPR119GHSR | |
| SCHEMBL19679355 | 0.65 | MAOA (0.42) | KLK7GPR119GHSR | |
| SCHEMBL21881810 | 0.64 | AGTR2 (0.52) | PTPN1 | |
| SCHEMBL21881523 | 0.64 | AGTR2 (0.52) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | KLK7 3842/4885PTPN1 4606/4885NAAA 2304/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | KLK7 3842/4885PTPN1 4606/4885NAAA 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.